Loading…
CTXR
Citius Pharmaceuticals, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 17322U306
$0.60-1.95%Price as of Aug 29, 18:37 UTC · updated once a day, after the close
Key metrics
- Market cap
- $16.53M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.75
- ROE
- -81.09%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.99
- 52-week high
- $2.19
- 52-week low
- $0.47
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -98.8% over 5Y.
today you would have $11.40▼ -98.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.78 | $4.00 | $18.92 | $19.75 | $38.50 | $25.50 | $25.50 | $26.00 | $95.00 | $166.50 | $693.75 | $390.00 | |
| P/S | 635.0x | — | — | — | 1283.4x | 2498.7x | 629.9x | 327.9x | 246.8x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PLURPluri Inc. | $1.53 | — | — | — | — | $16.51M |
| ADILAdial Pharmaceuticals Inc | $5.60 | — | — | — | -2011.64% | $16.43M |
| PLSMPulsenmore Ltd. | $2.57 | — | — | — | -17.62% | $16.71M |
| MDCXMedicus Pharma Ltd. | $0.26 | — |
About the company
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
- 23
- Cranford, United States
Company description provided by Yahoo Finance.